Is gabapentin an appropriate treatment for dysgeusia (bad taste) and burning mouth syndrome?

Gabapentin for Dysgeusia and Burning Mouth Syndrome

Gabapentin can be considered as a treatment option for burning mouth syndrome (oral dysesthesia), but there is insufficient evidence to support its use for dysgeusia (bad taste) alone.

Burning Mouth Syndrome (Oral Dysesthesia)

Evidence-Based Recommendation

The most recent guideline evidence supports gabapentin for moderate to severe oral dysesthesia/burning mouth syndrome. The 2024 NCCN guidelines recommend gabapentin (along with high-potency topical steroids or viscous lidocaine) for moderate to severe oral dysesthesia 1. This recommendation is based on randomized controlled trial data showing that 50% of patients (10 out of 20) receiving gabapentin experienced reduction in burning sensation 1.

Clinical Implementation

For burning mouth syndrome, start gabapentin at a low dose and titrate gradually:

• Initial dose: 100-300 mg once daily at bedtime
• Titration: Increase by 100-300 mg every 3-7 days as tolerated
• Target dose: 900-1800 mg daily in 2-3 divided doses (maximum 3600 mg/day)
• Timeline: Assess response after 2-4 weeks at therapeutic dose

The FDA label confirms common adverse effects include dizziness (17-28%), somnolence (19-21%), and peripheral edema (2-8%) 2. These side effects are dose-dependent and particularly problematic in older adults, necessitating the low-and-slow titration approach.

Alternative Formulations

Topical gabapentin (250 mg/mL solution, swish and spit) shows promise as a novel approach that may reduce systemic side effects. A 2023 retrospective study demonstrated a median 2-point reduction in burning scores on a 0-10 scale, with only 15.8% of patients reporting adverse effects 3. This topical approach warrants consideration before systemic therapy, though it requires compounding pharmacy access.

Combination Therapy

The evidence suggests combining gabapentin with alpha-lipoic acid may enhance efficacy. A randomized controlled trial showed 70% response rate with combination therapy versus lower rates with either agent alone, with 13.2 times greater odds of improvement compared to placebo 4. Consider alpha-lipoic acid 600 mg/day plus gabapentin 300 mg/day for refractory cases.

Dysgeusia (Bad Taste)

Limited Evidence

For dysgeusia without burning sensation, gabapentin has minimal supporting evidence. Only two case reports describe successful use:

• Two glioblastoma patients with chemotherapy-induced dysgeusia showed resolution within weeks of gabapentin initiation 5
• One case series used a topical compound containing gabapentin 10 mg (with memantine and MSG) showing improvement in 85% of patients 6

These isolated reports are insufficient to recommend gabapentin as standard therapy for dysgeusia. The mechanism proposed—addressing gustatory "deafferentation"—remains theoretical 5.

When Dysgeusia Accompanies Burning

If dysgeusia occurs alongside burning mouth syndrome, treat the burning component with gabapentin as outlined above. The 2024 NCCN guidelines specifically address oral dysesthesia (burning sensation) but do not separately recommend treatment for isolated taste disturbance 1.

Critical Caveats

Contraindications and Monitoring

• Renal impairment: Reduce starting dose to 100-200 mg/day; gabapentin is renally cleared 7
• Elderly patients: Start at lowest doses (100 mg/day) due to increased fall risk from dizziness and ataxia 7
• Avoid abrupt discontinuation: Taper gradually to prevent withdrawal symptoms (anxiety, insomnia, pain, sweating) 2

When NOT to Use Gabapentin

The 2020 ASCO guidelines explicitly state that gabapentin lacks evidence for chemotherapy-induced peripheral neuropathy, with multiple trials showing no benefit 8. This context is relevant because dysgeusia often occurs in the same chemotherapy setting, and clinicians should not extrapolate neuropathy data to taste disorders.

Context-Specific Considerations

For immunotherapy-related oral dysesthesia: The NCCN guidelines recommend holding immunotherapy for moderate-severe cases and using gabapentin alongside dietary modifications 1. This represents a specific clinical scenario where the underlying cause (immune checkpoint inhibitor toxicity) requires concurrent management.

For burning mouth syndrome in primary biliary cholangitis: Gabapentin is listed as a third-line option for cholestatic pruritus, but this is distinct from primary burning mouth syndrome 9. Do not confuse these conditions.

Practical Algorithm

1. Confirm diagnosis: Rule out odontogenic sources, mucosal lesions, nutritional deficiencies (B12, folate, iron, zinc), and medication causes
2. Assess severity: Mild (grade 1) burning may respond to topical measures alone
3. For moderate-severe burning mouth syndrome:
   • Consider topical gabapentin 250 mg/mL solution first if available 3
   • If unavailable or ineffective, initiate systemic gabapentin 100-300 mg at bedtime
   • Titrate every 3-7 days to 900-1800 mg/day in divided doses
   • Add alpha-lipoic acid 600 mg/day if partial response after 4 weeks 4
4. For isolated dysgeusia without burning: Gabapentin is NOT recommended based on current evidence
5. Reassess at 4-6 weeks: If no improvement, consider alternative diagnoses or refer to oral medicine specialist

The key distinction is that gabapentin has guideline-level support for burning mouth syndrome but only anecdotal evidence for dysgeusia alone.